Home > Insider Trading > Filing (0001437749-25-022863)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645469	Monopar Therapeutics	MNPR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333516	R Kim Tsuchimoto	1000 Skokie Blvd Suite 350 Wilmette IL 60091		Yes	No	No	No

Transaction Summary

Sold:	8,904 shares	Avg. Price: $40.00	Total Value: $356,170.68
Number of Shares After Transactions:	11,486 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-07-14	8,904	$0.01	20,390	No	4	X	Direct
Common Stock	Disposition	2025-07-14	8,904	$40.00	11,486	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2025-07-14	4,200	$0.00	4,200	$0.01
Common Stock	Stock Options	Disposition	2025-07-14	4,704	$0.00	4,704	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-04-04	No	4	X	Direct
0		2027-02-20	No	4	X	Direct

Footnotes

This transaction involved a cash exercise of stock options.
The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.
Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.